buy

Alnylam Pharmace. buy Truist Financial Co.

Alnylam Pharmace.

Start price

€283.30

/ 50%

Target price

13.04.27

Performance (%)

Price

Summary

This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of . This prediction currently runs until 13.04.27. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

AI-generated

Feedback

Performance without dividends (%)

Name	1w	1m
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Truist_Financial_Co_ for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 432.078

Change

Ends at

Alnylam Pharmaceuticals (ALNY) had its price target lowered by Truist Financial Corporation from $515.00 to $505.00. They now have a "buy" rating on the stock.

Ratings data for ALNY provided by MarketBeat

Truist Financial Co.